From Guidelines to Community Practice: Translating the Latest NCCN RRFL Updates Into Action

In 'From Guidelines to Community Practice: Translating the Latest NCCN RRFL Updates Into Action,' Tara Graff, DO, MS delves into the following critical questions:

What do you see as the most important recommendation updates regarding the latest NCCN guidelines in RRFL?

How are you translating these into the community practice, and where do challenges remain?

Tara Graff highlighted the significance of 2025 as a landmark year for RRFL treatment, with the June 2025 approval of tafasitamab plus R² and the November 2025 approval of epcoritamab plus R² representing two major additions to the NCCN guidelines that meaningfully expand the second-line treatment options available to follicular lymphoma patients beyond the R² backbone and signaling a clear directional shift toward novel, non-chemotherapy combinations that can deliver progression-free survival measured in years. She also addressed the persistent challenge of translating these guideline updates into community practice, noting that community oncologists managing a broad range of cancer types face a significant awareness gap, making proactive education and peer-to-peer communication essential tools for closing the gap between guideline publication and real-world adoption. Tara Graff emphasized that those with influence in the community oncology space have a responsibility to actively disseminate awareness of these updates through direct outreach, educational platforms, and institutional communications.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Empowering Community Oncology: Infrastructure Investments for Bringing Novel RRFL Therapies to Patients,' features Tara Graff advancing her conversation on follicular lymphoma and focusing on the most important infrastructure investments community oncology practices can make to support the safe and successful adoption of novel therapies in follicular lymphoma.